Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer

Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast cancer. Triple-negative breast cancer affects a small portion of all breast cancer subtypes, representing about 15% of tumors. It is more common in younger women, in black African American women, and those who are BRCA mutation carriers. Dr. Stearns shares her expertise on the management of patients with triple-negative breast cancer and some of the advances made in treatment.